Overview

Prevention of Recurrent Venous Thromboembolism (PREVENT)

Status:
Completed
Trial end date:
2004-08-01
Target enrollment:
0
Participant gender:
All
Summary
A multicenter randomized, double blind placebo controlled trial to determine the efficacy of long-term, low dose warfarin in the secondary prevention of venous thromboembolism.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
National Heart, Lung, and Blood Institute (NHLBI)
Treatments:
Warfarin
Criteria
Patients with venous thromboembolism, including patients with factor V Leiden. Patients had
completed prescribed anticoagulation therapy within the last two years before the trial and
were not currently on anticoagulation therapy.